MD安德森和黑曜石治疗宣布战略合作，以加速新型工程肿瘤浸润淋巴细胞治疗（Cytotil™）的实体肿瘤

MD安德森新闻Release November 18, 2020

The University of TexasMD安德森癌症中心和Obsidian Therapeutics, Inc.today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform withMD安德森’sextensive experience and state-of-the-art capabilities in TIL cell therapy, led by the生物学发展platform, within the治疗探测部门。

该协作的重点是开发具有受管制膜结合的IL15（称为Cytotil TM）的TIL装甲，其有可能提高抗肿瘤疗效，并降低患有不同类型实体瘤的患者的肿瘤负担。该团队将合作以加速细胞的发展，包括过程和分析发展和临床准备情况。

“直到治疗被赋予了治疗患有固体肿瘤患者的有希望的选择，尽管今天广泛使用的是受安全性和疗效挑战的限制，”罗贝阿拉亚，M.D.，副教授黑色瘤Medical Oncology在MD安德森。“We are pleased to work with Obsidian to advance their novel cytoTIL program, which has the potential to drive more durable treatment responses and expand TIL therapy to a broader group of our patients.”

The cytoTIL therapy is engineered using Obsidian's cytoDRiVE platform technology, which precisely and reversibly controls protein expression and activity using FDA-approved orally bioavailable drugs. By leveraging regulated membrane-bound IL15 to drive antigen-independent expansion of T cells and transactivation of NK cells, cytoTIL therapy is anticipated to improve patient response to TIL treatment and expand patient eligibility to those who currently cannot benefit from this transformative therapy.

“We are delighted to work withMD安德森’s生物学开发团队建立第一代直到疗法的成功，并尽可能迅速地将首次可控的直到治疗疗法带来，“说保罗·沃顿，博士。黑曜石治疗学的首席执行官。“通过其细胞疗法研究平台，深入的临床开发经验，以及工乐动体育LDsports中国业制造能力，MD安德森is a best-in-class collaborator to advance and accelerate cutting-edge cell therapies.”

MD安德森’s生物制剂开发平台围绕一支经验丰富的团队建造，专注于开创性的生物治疗剂，包括抗体和细胞疗法。具有最先进的60,000平方英尺的脚GMP细胞治疗制造设施，平台加入MD安德森具有工业发展严谨的专业知识。生物制剂的发展为早期公司提供了强大的起点，以获得广泛的宽度MD安德森细胞治疗发展中的能力。

MD安德森正在实施的Institutional Conflict of Interest Management and Monitoring Plan对于与这种关系有乐动体育LDsports中国关的任何研究。